Full-Time
Senior Phlebotomist
Natera
5,001-10,000 employees
Genetic testing for cancer, transplant, pregnancy
No salary listed
Company Historically Provides H1B Sponsorship
Mt Airy, NC, USA
In Person
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Natera
See people who can refer or advise you
- A minimum of 5 years of phlebotomy experience is required.
- A high school diploma or equivalent is required.
- A phlebotomy certificate is required if required by the state.
- Employees must complete HIPAA/PHI privacy, General Policies and Procedure Compliance, and security training within the first 30 days of hire.
- Employees must maintain current status on Natera training requirements.
- The ability to adhere to professional standards, hospital policies and procedures, federal, state, and local requirements, and Joint Commission standards is required.
- The position requires tracking each blood draw.
- The role requires working in an office setting while wearing scrubs.
- Verify test requisitions by comparing information with the nursing station log and bring discrepancies to unit personnel's attention.
- Verify patients by reading patient identification.
- Obtain blood specimens by performing venipunctures and finger sticks.
- Maintain specimen integrity by using aseptic technique, following department procedures, and observing isolation procedures.
- Track collected specimens by initialing, dating, and recording collection times, and maintain daily tallies of collections performed.
- Maintain quality results by following department procedures and testing schedules, recording results in the quality-control log, and identifying and reporting needed changes.
- Maintain a safe, secure, and healthy work environment by following standards and procedures and complying with legal regulations.
- Resolve unusual test orders by contacting the physician, pathologist, nursing station, or reference laboratory; refer unresolved orders to the originator for clarification and notify the supervisor.
- Participate in educational opportunities, read professional publications, maintain professional networks, and participate in professional organizations.
- Manage logistics and print patient reports for the assigned area.
- Answer and triage billing questions and follow up with patients.
- Schedule courier-service pickups through FedEx or Medspeed.
- Handle protected health information in paper and electronic form using the technologies needed to perform the job.
- A Bachelor of Science or Bachelor of Arts degree is preferred.
Natera provides genetic testing and diagnostics using cell-free DNA (cfDNA) from a patient’s blood to guide medical decisions. Its tests include MRD and ctDNA profiling for cancer, the personalized Signatera test, organ transplant health assessment, and Panorama NIPT for prenatal screening. The company combines cfDNA-based results with remote access and genetic counseling to support clinicians and patients. Its goal is to deliver accurate, noninvasive tests that improve treatment decisions and patient outcomes at scale.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Get referred to Natera
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $752.8 million, up 37.7%, and guidance rose to $2.91 billion.
- Signatera volume exceeded 280,000 units in Q2 2026, adding 34,000 sequentially.
- Eledon chose Prospera for its 600-patient Phase 3 kidney-transplant trial on June 25, 2026.
What critics are saying
- Guardant, Illumina, Tempus, and Abbott are attacking MRD with faster, broader platforms.
- Natera still spends heavily on FIND-CRC before revenue, pressuring 2026 margins.
- If payers cap Signatera ASP below $2,000, MRD economics collapse into commoditization.
What makes Natera unique
- Signatera became Japan’s first PMDA-approved MRD test after June 2026 colorectal approval.
- FDA approved Signatera’s bladder-cancer companion diagnostic in May 2026.
- Natera’s Austin expansion targets the world’s largest genomics laboratory, reinforcing scale.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible medical plans
Investment options
Time off
Workplace perks
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Natera reported second-quarter results that beat analyst expectations, driven by strong test volume growth and momentum across its product portfolio. Revenue reached $752.8 million, exceeding estimates by 13.6%, whilst adjusted EPS of -$0.47 beat forecasts. CEO Steven Chapman attributed the performance to record test volumes, particularly for Signatera in oncology, and the launch of an enhanced Panorama prenatal test. The company secured FDA and Japanese regulatory approvals for Signatera during the quarter. Operating margin improved to -10.1% from -20.2% year on year. Sales volumes rose 22.4% compared to the prior year. During the earnings call, analysts questioned the sustainability of Signatera's growth trajectory and future pricing potential. Chapman acknowledged emerging competition in MRD testing but noted that low market penetration leaves substantial room for expansion.
Natera spotlights record Signatera volumes, raises outlook at Canaccord Conference. August 15, 2026 Key points. * Natera raised its outlook after broad-based second-quarter momentum, including record Signatera volumes, strong revenue and pricing, improved gross margins, and narrowing losses despite continued investment. * Signatera volumes exceeded 280,000 units, rising about 34,000 sequentially, supported by clinical data, regulatory and guideline milestones in bladder cancer, and recent commercial expansion. * Natera is expanding laboratory capacity and international coverage while investing heavily in early cancer detection; its FIND-CRC study is nearing enrollment completion, though the program currently weighs on profitability. * MarketBeat previews top five stocks to own in September. Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels. Speaking at the Canaccord Genuity Growth Conference, Brophy said Natera raised its outlook following a quarter in which volume performance was broad-based. He described organ health momentum as "very strong" and said women's health posted high-single-digit year-over-year growth despite typically experiencing seasonal sequential declines. Women's health momentum and product updates. Brophy attributed part of the women's health performance to uptake of Natera's Fetal Focus offering, which launched several quarters ago and continued to gain traction through the second quarter. He also highlighted the June launch of a new version of the Panorama non-invasive prenatal testing assay. The updated Panorama test is designed to offer greater sensitivity, particularly in cases with low fetal fraction, an area that Brophy said has historically been challenging for non-invasive prenatal testing. Because the launch occurred in early June, he said it was not a significant driver of second-quarter results but could support women's health performance during the remainder of the year. While Brophy characterized the quarter as exceptional, he said his typical framework for women's health is mid-single-digit volume growth, with the opportunity for faster revenue growth if Natera can increase reimbursement realization for covered services. Record Signatera volumes. The company's oncology business, led by its Signatera molecular residual disease and recurrence-monitoring test, reached more than 280,000 units during the quarter. Brophy said the company added approximately 34,000 units sequentially, compared with a prior quarterly record increase of about 25,000 units. He noted that first-quarter Signatera volumes were somewhat affected by weather-related disruptions. Natera estimates that roughly 2,000 to 4,000 units that otherwise may have been received in the first quarter arrived later, contributing to the magnitude of the second-quarter sequential increase. Even excluding that effect, Brophy called the quarter an "absolute blowout." He cited several drivers of Signatera's growth: * Continued generation of clinical outcomes data for Signatera and molecular residual disease testing. * FDA approval related to Signatera's use in muscle-invasive bladder cancer. * Inclusion in National Comprehensive Cancer Network guidelines for muscle-invasive bladder cancer in June. * The full operational impact of a commercial expansion completed around April. Brophy said newer offerings, including Genome and Latitude, accounted for only a small portion of total Signatera volume. However, he said their availability broadens the company's product menu and may enhance Signatera's positioning with physicians. Coverage, international expansion and laboratory investment. Natera expects to continue pursuing reimbursement coverage on a tumor-type-by-tumor-type basis, Brophy said. He described the company's interactions with MolDX, Medicare's molecular diagnostic services program, as positive and said Natera has now achieved coverage across much of the critical mass of common tumor types. The company is now working on additional, less common cancers, he said. In Japan, Natera has received PMDA approval for Signatera and has submitted for bladder cancer coverage following its approval in colorectal cancer. Brophy said the company remains on track for an early 2027 Japanese launch. The next steps include discussions with Japanese agencies regarding the number of reimbursed testing time points and pricing, which he expects to be addressed in the second half. The company is also expanding laboratory capacity. Brophy said Natera's Austin, Texas, laboratory is expected to become the world's largest genomics laboratory once its current expansion is completed. First-half capital expenditures increased to approximately $85 million from about $45 million in the prior-year period. He said the elevated spending level is not expected to represent ongoing maintenance capital expenditures, which he estimated at closer to $60 million annually. Early cancer detection investment. Brophy said Natera remains ambitious in early cancer detection, where its FIND-CRC study is approaching enrollment completion at up to 40,000 patients. He emphasized the expense and complexity of bringing a blood-based early cancer detection assay to market, estimating that a company may need to spend roughly $500 million before selling its first test when clinical development and regulatory work are included. Rather than immediately building a large commercial team, Brophy said Natera expects to use a phased approach, deploying an initial group of sales representatives in selected geographies and expanding based on early results and returns on invested capital. He acknowledged that early cancer detection spending is currently weighing on the company's overall profit profile because the program is generating operating expenses without revenue or gross profit. Still, he said Natera is seeing losses narrow while continuing to invest in research and development, Signatera clinical studies and commercial growth initiatives. Looking internationally, Brophy said Natera sees significant demand for Signatera in Europe following IVDR approval. He said reimbursement opportunities will need to be evaluated country by country and use case by use case, while noting that the company is conducting clinical studies in Europe, including CIRCULATE-France. About Natera (NASDAQ:NTRA). Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients. Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Natera, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list. While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Genetic testing company Natera reported second-quarter revenues of $752.8 million, up 37.7% year on year and beating analyst estimates by 13.6%. The company raised its full-year revenue guidance to $2.88 billion, 3% above consensus. Sales volumes rose 22.4% year on year. CEO Steven Chapman attributed the results to record test volumes, particularly for Signatera in oncology, and the launch of an enhanced Panorama prenatal test. The quarter also saw FDA and Japanese regulatory approvals for Signatera. Operating margin improved to -10.1%, up from -20.2% in the same quarter last year. Management linked this to higher average selling prices and scaling of recently launched products. The company expects continued volume growth across its testing franchises, with investments in clinical trials and early cancer detection driving future expansion.
NTRA stock surges after big earnings beat and guidance hike. BRYCE TUOHEY - UPDATED AUG. 7, 2026, 12:33 PM ET Positive clinical trial results for Natera Inc.'s genetic testing platform fueled strong investor optimism as stocks have been trading up by 18.7 percent Key takeaways traders need to know. * Q2 revenue jumped to $752.8M, crushing the $661.2M consensus estimate and signaling powerful demand momentum. * The company reported a Q2 loss of $0.47 per share, slightly better than the expected $0.49 loss, showing gradual operating leverage. * Full-year 2026 revenue guidance was raised to $2.85B-$2.91B, above the prior $2.74B-$2.82B range and the $2.80B Street consensus. * After the beat-and-raise print, NTRA ripped more than 12% in after-hours trading as momentum players piled in. * Management also advanced its Signatera MRD test in Japan, filing with the PMDA for bladder cancer to extend its colorectal cancer approval. Live Update At 12:32:28 EDT: On Friday, August 07, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 18.7%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Natera Inc. just delivered the kind of earnings print traders watch for all year. Q2 revenue came in at $752.8M, far ahead of the $661.2M consensus, confirming that NTRA's testing volume and oncology franchise are scaling fast. That top-line surprise explains why the stock exploded more than 12% after hours. On the bottom line, NTRA still lost money, but the direction matters. The Q2 loss of $0.47 per share was slightly better than the expected $0.49 loss. For a high-growth diagnostics name, a narrower loss alongside a huge revenue beat tells traders that operating leverage is starting to kick in, not falling apart. The chart backs up that read. Before earnings, NTRA had been grinding between roughly $260 and $280 for weeks. After the report, the stock gapped up, opening near $320.89 and closing around $315.04 on 2026/08/07, locking in a major range expansion. Intraday 5-minute candles show early volatility from $306.38 up to the $320+ area, then tight consolidation around $314-$316 - classic post-gap digestion. Under the hood, the fundamentals match the price action. Natera's trailing revenue is about $2.31B, growing over 40% annually. Gross margin sits at a strong 65.1%, but profitability ratios remain negative, with return on equity and return on assets still deep in the red. The balance sheet, however, is relatively clean: low debt (total debt-to-equity about 0.13), a current ratio around 3, and over $1.08B of cash on hand. For traders, that mix - high revenue growth, strong gross margins, negative but improving earnings, and solid liquidity - screams "aggressive growth story," not distress. NTRA trades rich on sales (price-to-sales near 15.7), so this is a momentum name where execution and guidance matter more than classic value metrics. When Natera beats and raises like it did here, the market tends to pay up. Why traders are locked in on NTRA now. NTRA just checked off several boxes that momentum and breakout traders track closely: big beat, guidance raise, regulatory wins, and explosive price reaction. That combination pulled Natera Inc. out of a choppy mid-$260s channel and into the $300-plus zone in one move. The core driver is growth. Natera's Q2 performance was powered by record testing volumes and strong oncology demand. The company isn't just selling more tests; it's doing so while layering in regulatory approvals, reimbursement wins, and product improvements across platforms like Signatera. For trading purposes, that creates a clear narrative: revenue acceleration backed by structural, not temporary, tailwinds. Guidance is the second major catalyst. Management lifted full-year 2026 revenue expectations to $2.85B-$2.91B, versus prior guidance of $2.74B-$2.82B and the Street at $2.80B. When a high-multiple name like NTRA guides above consensus, traders often read it as permission for a re-rating. The market did exactly that, sending NTRA more than 12% higher in after-hours trading as shorts scrambled and breakout traders chased. The third piece is pipeline and geography. Natera has now submitted its Signatera minimal residual disease test to Japan's PMDA for use in muscle-invasive bladder cancer, building on its prior Japanese approval in colorectal cancer. That move aligns with recent U.S. FDA approval and inclusion in NCCN guidelines for the same bladder cancer indication. For traders, this is more than science - it signals future revenue streams and international leverage built around a flagship product. There is also background noise from multiple Form 4 insider filings in NTRA, but without details on size or direction, those reports are hard to trade off. The real story is on the tape and in the fundamentals: a high-growth diagnostics name proving it can beat expectations and extend its global oncology footprint. Conclusion. For active traders, NTRA is now a textbook example of how strong fundamentals, clear catalysts, and clean charts can align. Natera crushed Q2 revenue expectations, modestly narrowed its loss per share, and then raised full-year 2026 revenue guidance above consensus to the $2.85B-$2.91B range. The market responded instantly, with NTRA spiking more than 12% in after-hours action and then holding much of that move as regular trading resumed around the $315 area. At the same time, Natera kept pushing its strategic product story. Signatera already has PMDA approval in colorectal cancer and now sits with a fresh submission in Japan for muscle-invasive bladder cancer, on top of recent U.S. FDA approval and NCCN guideline support for that same indication. That kind of regulatory momentum gives traders something to lean on beyond one earnings print. Still, NTRA is not a low-risk, cash-cow name. Margins are negative, returns on capital remain in the red, and the valuation is rich, which means the stock is highly sensitive to execution and sentiment. This is exactly why rules matter. As Tim Sykes likes to remind traders, "Cut losses quickly, because big winners are irrelevant if one stubborn trade wipes you out." As millionaire penny stock trader and teacher Tim Sykes, says, "There is always another play around the corner; don't chase just because you feel FOMO.". Natera Inc. is offering a powerful trading setup right now, but it is still just that - a trade, not a guarantee. This article is for educational and research purposes only and is not investment advice. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: One-of-a-kind AI play revealed. If you'd put $2,000 into Nvidia back in 2020, you'd be sitting on more than $30,000 today. The stock's been an absolute monster... But if you think you missed the boat, then you need to see this urgent message TODAY. Because not only am I revealing why the REAL AI boom is only just getting started... I'm also going to show you my top AI recommendation that's been CRUSHING it in this market. It has nothing to do with Nvidia... or Meta... or OpenAI... or anything else you're probably thinking. It's a unique AI play I'm certain you're not hearing from anyone else... One that could give you the chance to target an entire YEAR of peak Nvidia potential... In just one day. How much has this post helped you? (0 votes, average: 0 out of 5)
NTRA stock surges after big earnings beat and guidance hike. TIM BOHEN - UPDATED AUG. 7, 2026, 12:32 PM ET Natera Inc. stocks have been trading up by 18.71 percent after strong clinical data boosted investor confidence in its diagnostics portfolio. Key takeaways. * Q2 revenue came in at $752.8M, crushing the $661.2M consensus and signaling powerful volume growth for NTRA's testing business. * The company reported a Q2 loss of $0.47 per share, slightly better than expectations for a $0.49 loss, showing gradual margin improvement. * Full-year 2026 revenue guidance was raised to $2.85B-$2.91B, above both the prior $2.74B-$2.82B range and the $2.80B Street forecast. * Shares of NTRA jumped more than 12% in after-hours trading after the Q2 beat and outlook boost. * The Signatera minimal residual disease test was submitted to Japan's PMDA for use in muscle-invasive bladder cancer, expanding on existing approval in colorectal cancer. Live Update At 12:32:13 EDT: On Friday, August 07, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 18.71%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Natera Inc. (NTRA) just delivered the kind of quarter momentum traders look for. Q2 revenue hit $752.8M, far ahead of the $661.2M consensus. That kind of top-line beat tells you demand for NTRA's genetic and oncology testing remains strong and is likely accelerating. Yes, NTRA is still unprofitable. The company posted a Q2 loss of $0.47 per share, but even that was slightly better than the expected $0.49 loss. When a growth name pairs big revenue upside with a narrower loss, traders read it as operating leverage starting to kick in. On the chart, NTRA has been in a steady uptrend. The stock closed at $265.38 on 2026/08/06 and ripped to $315.50 on 2026/08/07, a powerful post-earnings move that confirms buyers are in control. Intraday, the 5-minute tape shows tight trading between roughly $311 and $318, with dips getting bought and the stock finishing near highs. That kind of price action often reflects strong institutional interest. Longer term, Natera is a high-valuation name, with a rich price-to-sales ratio around 15.7 and negative returns on equity. For traders, that means the story is all about growth and execution. As long as NTRA keeps beating revenue expectations and tightening losses, the market tends to forgive red ink. Why traders are watching Natera right now. NTRA lit up screens after its latest earnings release, and for good reason. This wasn't a mild "in line" report. Natera smashed expectations, and the stock's more than 12% after-hours jump shows the surprise was real. The core driver is simple: growth. Natera's $752.8M Q2 revenue didn't just beat the $661.2M estimate; it blew past it. For a diagnostics and genomics name, that scale of upside usually means testing volumes are running hot, especially in oncology where pricing is stronger. Traders who focus on momentum know that when a company consistently outperforms on the top line, funds often chase the story. Earnings were still negative, but NTRA's $0.47 per-share loss came in a bit better than the expected $0.49 loss. That may sound small, yet it signals operating discipline. Combine that with a gross margin above 65%, and you have a setup where every new dollar of revenue can improve the bottom line over time. The bigger tell, though, is guidance. Natera raised its 2026 revenue outlook to $2.85B-$2.91B, up from $2.74B-$2.82B and clearly above the $2.80B consensus. When management pushes guidance above Wall Street, it's a loud statement of confidence. Traders in NTRA are reacting to that, not just the rear-view numbers. On top of earnings, Natera is extending its global reach. The company submitted its Signatera minimal residual disease test to Japan's PMDA for approval in muscle-invasive bladder cancer, building on existing PMDA approval in colorectal cancer. That move, backed by recent U.S. FDA approval and NCCN guideline inclusion for the same indication, deepens the moat around Signatera. For growth-focused traders, expanding regulatory footprints like this support the idea that NTRA's oncology franchise has a long runway. Conclusion. For active traders, NTRA is a textbook example of a catalyst-driven move. Strong Q2 revenue, a slightly better-than-feared loss, and a clear hike in full-year guidance have combined with a high-momentum chart. The stock's jump from the mid-$260s to the mid-$310s in one day tells you how underpriced the growth story may have been heading into the print. At the same time, Natera remains a high-risk, high-reward name. The company is unprofitable, with negative returns on assets and equity, and a rich valuation that depends on continued execution. The balance sheet, with a current ratio around 3 and modest leverage, gives NTRA room to keep investing, but traders must remember this is still a growth play, not a steady cash cow. As Tim Bohen, lead trainer with StocksToTrade says, "A good trade setup checks all the boxes - volume, trend, catalyst. Don't trade if you're missing pieces of the puzzle." That framework applies here: NTRA's liquidity, chart strength, and fundamental news all aligned to create a compelling short-term trading opportunity. The Signatera expansion into Japan via the PMDA submission reinforces Natera's strategy: build a global oncology diagnostics platform anchored in strong regulatory support and clinical guidelines. If that strategy continues to work, the raised 2026 revenue range of $2.85B-$2.91B may not be the last upgrade. For those studying NTRA as a trading case study, the message lines up with what Tim Sykes teaches: "React to the news, don't predict it. Let the earnings, the guidance, and the price action confirm the trade, and always be ready to cut losses fast if the story changes." This analysis is for educational and research purposes only and is not advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. Why top traders call it "money Monday" If you hate Mondays... That's probably because you don't know about MONEY MONDAYS. Most traders don't know this but... There's a unique kind of trade you can make every Monday morning... That often delivers more gains in 1 day than most people see in a year. Like on one recent Monday... When you could have ridden MSS for a +149% in one day. Even with a small $1,000 starting stake... that's almost $1,500 profit potential! Of course, I can't promise you future returns or against losses... But it's almost that time again. Will you join StocksToTrade, Inc.?